|
| |
SLIL BiomedicalSLIL Biomedical Corp. is an early-stage drug discovery company, focused on developing new treatments for cancer and other diseases. SLIL has patented technology and a pipeline of potential drugs, the first of which is expected to enter a human clinical trial for cancer in early 2002.
SLIL has a strong board and well-qualified management. The Company also has outstanding scientific resources, led by Dr. Laurence Marton and Dr. Benjamin Frydman. Dr. Marton is considered a leading expert in the field of polyamines and their role in cell function and human disease, while Dr. Frydman is a world-renowned organic chemist and a leader in the field of porphyrin research.
| Contact Details: |
| 37 Kessel Court, Suite 211 |
| Madison |
| Wisconsin |
| 53711-6233 |
| United States of America |
| Tel: | 608-270-3712 |
| Fax: | 608-270-3715 |
| Email: | mkjohnson@slil.com |
| WWW: | www.slil.com/
|
|
Loading...
|
Recent Publications by SLIL Biomedical: |  |
Long-chain polyamines (oligoamines) exhibit strong cytotoxicities against human prostate cancer cells.
alpha N,(omega)N-bis(ethyl) octamine SL-11160, decamine SL-11159,... | 13th November, 2004
| SLIL Biomedical Corp., 535 Science Drive, Suite C, Madison, WI 53711, USA.
| Bioorg Med Chem. 2003 Sep 1;11(18):4121-31.
|
Macrocyclic polyamines deplete cellular ATP levels and inhibit cell growth in human prostate cancer cells.
In solid tumors, when O(2) partial pressure drops below 10 mmHg, ATP... | 6th April, 2004
| SLIL Biomedical Corp., 535 Science Dr., Suite C, Madison, Wisconsin
| J Med Chem. 2004 Feb 12;47(4):1051-9.
DOI Direct Link |
Cyclopropane-containing polyamine analogues are efficient growth inhibitors of a human prostate tumor xenograft in nude mice.
Polyamine analogues 7, 10, 18, 27, and 32 containing cyclopropane rings... | 13th November, 2003
| SLIL Biomedical Corporation, 535 Science Drive, Suite C, Madison, WI
| J Med Chem. 2003 Oct 9;46(21):4586-600.
DOI Direct Link |
HIV insertions within and proximal to host cell genes are a common finding in tissues containing high levels of HIV DNA and macrophage-associated p24 antigen expression.
HIV integration within host cell genomic DNA is a requisite step of the... | 2nd August, 2003
| SLIL Biomedical Corporation, Menlo Park, California, USA.
| J Acquir Immune Defic Syndr. 2003 Jul 1;33(3):308-20.
|
A novel polyamine analog (SL-11093) inhibits growth of human prostate tumor xenografts in nude mice.
PURPOSE: We tested the polyamine analog SL-11093... | 30th July, 2003
| SLIL Biomedical Corporation, Suite C, 535 Science Dr, Madison, WI
| Cancer Chemother Pharmacol. 2003 Jun;51(6):488-92. Epub 2003 Apr 15.
DOI Direct Link |
→View more SLIL Biomedical research publications. |
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 718 times since April 2007, the link to the organisation's website has been followed 107 times Recent Search Terms used to find this page: t | SLIL Biomedical | polyamine, HIV | slil biomedical | slil biomedical | Madison research lab | SLIL Biomedical | novel polyamine analog conjugates as therapies for cancers and prostate disease | slil | SLIL | . Search for more companies in Madison Search for more companies in Wisconsin This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for SLIL Biomedical |
